Empowering Health Innovation

Through Strategic Partnerships

A Legacy Of Impact & Growth

Key Highlights

Key Highlights

We guided our clients through
complexity, providing clarity,
insight, and a strategic path to
success.

Global Reach and Access

Our network and expertise
opened doors to markets across
Europe, Latin America, Canada,
and the USA, among others.

Tailored Solutions for Unique Needs

No two clients were the same.
We built tailored services that
met specific needs—from
valuable insights to strategic
partnerships.

Measurable Results

100+

Clients

300+

Engagements

200+

Strategic Partnerships

35+

Countries

22+

Years

Social Impact · Reaching millions of patients worldwide.

Case Studies

trifermed NEWS

LinkedIn Logo The trifermed Awards
for Social Impact in Healthcare
Celebrates its 8th Edition
Date: July 16, 2024

The 8th edition of the trifermed Awards for Social Impact in Healthcare is here! Join us on September 17, 2024 for an evening of celebration, innovation, and inspiration.

This year's awards recognize four outstanding individuals and organizations whose work exemplifies the spirit of social responsibility and innovation in healthcare. We invite you to join us for this unforgettable evening.

Case Study: Valeo - Deployer
Strategic portfolio expansion & licensing partnership in the Parkinson’s treatment space
Date:
Valeo Case Study Image

A Canadian specialty pharma company engaged Trifermed to expand its CNS portfolio. Through strategic asset scouting and partner negotiation, they secured exclusive rights to a novel Parkinson’s treatment from a European company. This licensing deal positioned them as a key player in the Canadian neurodegenerative disease market.

Case Study: Carnot
First sublingual immunotherapy sprays for respiratory and urinary infections in Mexico
Date:
Carnot Case Study Image

Carnot partnered with Trifermed to identify and license innovative immunotherapies from Europe. Through Trifermed’s support, Carnot secured a deal with Inmunotek to launch Bactek® SL and Uromune® SL in Mexico—the first sublingual sprays to prevent respiratory and urinary infections—positioning Carnot as a leader in immunotherapy innovation.

LinkedIn Logo trifermed Welcomes Jordi Plaja
as Senior Strategic Advisor, Biopharmaceuticals,
Marking a New Chapter in Health Innovation
Date: March 27, 2024

We're thrilled to share a significant milestone in trifermed’s journey. Please join us in welcoming Jordi Plaja Portell as our Senior Strategic Advisor in Biopharmaceuticals.

With Jordi’s illustrious 25-year trajectory in healthcare, spanning leadership roles and profound impacts across multinational pharmaceuticals and tech ventures, we're set to amplify our influence in health innovation.

Case Study: Cipher - Developer
Expanding dermatology and pain management products into Latin America
Date:
Cipher Case Study Image

To expand into Latin America, a Canadian specialty pharma company partnered with Trifermed to launch an isotretinoin product in Brazil and extended-release tramadol in multiple countries. Trifermed facilitated strategic alliances with partners from India and Uruguay, enabling efficient market access and long-term collaboration across the region.

Case Study: Biologics Portfolio
Enabling access to global biosimilars in Brazil through strategic partnership
Date:
Biologics Case Study Image

A Brazilian pharmaceutical company partnered with Trifermed to expand its biologics portfolio through strategic licensing. Trifermed facilitated a deal with a global biosimilar manufacturer, enabling regulatory and commercial entry into Brazil’s high-demand biologics market with differentiated, internationally registered therapies.

LinkedIn Logo The trifermed Awards
for Social Impact in Healthcare 2025:
10th Anniversary Edition!
Date: December 1, 2024

As we begin the journey toward the trifermed Awards 2025, we celebrate not just the tradition but the evolution of these awards.

This year, we’re thrilled to welcome Dra. Elena Carreras to our panel of experts—proof that the impact of past winners lives on through their continued contributions. We invite all past guests, friends and new guests to join us for this milestone celebration. Save the Date: September 16th, 2025

LinkedIn Logo Boston-Based Communications Strategy Group
And Barcelona-Based trifermed Announce Strategic Alliance
Date: March 15, 2024

We are thrilled to announce a strategic alliance with The Communications Strategy Group Inc. (CSG), a milestone that intertwines with our vision set forth during our expansion into North America last December.

This alliance embodies our continuous effort to bridge innovative health solutions across borders, reinforcing our Cambridge, MA and Barcelona bases as pivotal hubs for transformative healthcare innovation.

LinkedIn Logo Trifermed and CSSi LifeSciences Join Forces
to Accelerate Global Healthcare Innovation
Access into the U.S. Market
Date: January 6, 2025

Trifermed is thrilled to announce the official launch of our strategic partnership with CSSi LifeSciences at the 2025 J.P. Morgan Healthcare Conference in San Francisco!

This partnership represents a powerful collaboration to accelerate global healthcare innovation and enable biopharma, MedTech, and digital health companies to successfully access the U.S. market.

Case Study: Developer
Pioneering a first-in-class Phase II-ready novel topical treatment for Periodontitis
Date:
Case Study Image

A U.S. dental research spin-off sought partners to finalize and commercialize its first-in-class topical treatment for periodontitis. By working with Trifermed to design and validate its business model, the company secured a co-development and licensing agreement covering the Nordics, Baltics, Iceland, and Russia, paving the way for Phase II readiness.

Case Study: Mecwins-Quidel
Co-developing an ultra-sensitive diagnostic technology in the Point-of-Care space
Date:
Mecwins Case Study Image

Mecwins partnered with Trifermed to secure a global co-development and licensing agreement with Quidel. The collaboration leveraged Mecwins’ ultrasensitive AVAC technology and Quidel’s expertise in point-of-care diagnostics, enabling product development, regulatory advancement, and market validation in the IVD space.

Case Study: Undisclosed (Dermatology)
Expanding dermatology portfolio through a novel topical therapy for hyperhidrosis
Date:
Dermatology Case Study Image

A Mexican pharmaceutical company partnered with Trifermed to license a novel EU-approved topical treatment for severe primary axillary hyperhidrosis. This collaboration enabled exclusive commercialization in Mexico, Peru, and Colombia, reinforcing the company’s dermatology portfolio with a first-in-class solution and a strong regulatory launch strategy.

LinkedIn Logo New Milestone in Partnership
with Achelous Partners;
Achelous Welcomes Prof. Sergi X. Trilla
Date: December 6, 2024

We are proud to announce that our Founder and President, Prof. Sergi X. Trilla, MD, MBA. , has joined Achelous Partners as their European Representative in Spain.

This partnership allows us to extend our support to clients all over the world by offering expert M&A services through Achelous Partners, enhancing our already robust portfolio in the biotech, medtech, and digital health sectors.